sintilimab combined with anlotinib
Phase 2Small molecule
sintilimab combined with anlotinib is one of 5 small molecule programs targeting Sintilimab. It is currently in Phase 2.
1
Indications
3
Total Trials
1
Active Trials
4
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Sintilimab
#DrugCompanyPhaseTrials
1Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Lenvima
EisaiPhase 3
Experimental Drug
MMedesis Pharma SA
Phase 3
Sintilimab Plus Chemotherapy
FFudan University
Phase 2
sintilimab combined with anlotinib
ZZhejiang Cancer Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Metastatic NSCLC1 trial
Sintilimab1 trial
Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
Not yet recruiting·FFirst Affiliated Hospital of Wannan Medical College·Phase 2·NCT07022301·25 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang Cancer Hospital